Olea Sphere Medical Imaging Software is Granted USFDA Approval

In IT
Fri, 17 Jan 2014

Olea Medical, a medical technology developer with headquarters at La Ciotat, France, and offices in Cambridge, MA, US, has obtained FDA 510(k) clearance to market the 2.3 version of Olea Sphere medical imaging enterprise software package in the US.

Olea Sphere is an image processing software package intended for picture archive, post-processing and communication. It helps standardise both viewing and analysis capabilities of functional and dynamic imaging datasets acquired with MRI and CT across vendors. It features innovative image viewing and analysis, processing of perfusion weighted image post-processing, permeability computation, as well as diffusion weighted image/tensor image post-processing, fiber tracking post-processing, and longitudinal analysis of multiple time points.

It is compliant with the DICOM standard and Windows, Macintosh or Linux operating systems. It runs on any standard off-the-shelf workstation or it can be used through a thin deployment with a server. Olea Sphere 2.3 was CE marked in October 2013 and received FDA 510(k) clearance end of December 2013.  

“The FDA clearance of this new version of our image processing software package is an important milestone for Olea Medical. Indeed, among other significant new features, this package includes now our Bayesian post-processing proprietary algorithm, the result of over 3 years of investment in research and innovation”, said Fayçal Djeridane, President and CEO of Olea Medical. “Such an accomplishment reinforces our confidence in our science-based strategy and positions us as the worldwide leader in CT and MR perfusion imaging post-processing. But, most importantly, such innovative applications will lead the way towards standardised image post-processing in routine clinics, greatly facilitating doctors’ reading work and image interpretation for the utmost benefit to patients”, he added.

Along with the Bayesian post-processing method, Olea Sphere 2.3 also features a T1 mapping plug-in a unique subtraction option dedicated to lesion progression follow-up in patients with long-term diseases.

Source: Olea Medical

15 January 2014

«« HP Saves Data Centre Space, Time, Costs for Belfast Trust

Calgary Scientific Joins the Technology Alliance Partnership of Hitachi Data Systems »»

CT, Imaging, MRI, Visualisation, CT scans, dynamic imaging, imaging software, Olea Medical

Latest Articles

Decision-Making in the ICU
- Journal Article
- 19/04/2024
Decision-making in the ICU is a multifaceted process that involves clinical assessment, collaboration among multidisciplinary teams, ethical considerations, evidence-based practice, communication, and continuous adaptation to evolving clinical scenarios. Balancing the complex factors requires
READ MORE
Dealing With Uncertainty in ICU Decision-Making: A Practical Guide
- Journal Article
- 19/04/2024
When the stakes are high, and the path ahead is uncertain, the decisions made, especially if a patient continues to worsen, can be sources of self-torment and can haunt us for a long time. Our goal is to suggest ways to steer decision-making for intensivists in the face of uncertainty by prop
READ MORE
The Least Bad Decision: Crisis Standards of Care After the Pandemic
- Journal Article
- 19/04/2024
COVID-19 was an emergency that lasted for years and left few regions of the world untouched. The pandemic shone a spotlight on both the strengths and weaknesses of our disaster planning. What worked, what did not, and how can we better plan for future emergencies? The COVID-19 pandemic fo
READ MORE

CT, Imaging, MRI, Visualisation, CT scans, dynamic imaging, imaging software, Olea Medical Olea Medical, a medical technology developer with headquarters at La Ciotat, France, and offices in Cambridge, MA, US, has obtained FDA 510(k) clearance to...